Pharmaceutical Technology

DECEMBER 5, 2023

Nitric oxide is under clinical development by SaNOtize Research and Development and currently in Phase II for Warts. According to…

Development 100

Development Research Clinical Development 100

Pharmaceutical Technology

DECEMBER 5, 2023

Nitric oxide is under clinical development by SaNOtize Research and Development and currently in Phase II for Warts. According to…

Development 100

Development Research Clinical Development 100

Pharmaceutical Technology

DECEMBER 6, 2023

Nitric oxide is under clinical development by SaNOtize Research and Development and currently in Phase II for Warts.

Development 100

Development Research Clinical Development 100

Outsourcing Pharma

APRIL 7, 2022

Experts from the Decentralized Trials and Research Alliance and Rafael Pharmaceuticals discuss progress and possibilities during Clinical Development Advances.

Clinical Development 75

Clinical Development Development Trials Research 75

Medical Xpress

MARCH 23, 2023

Researchers at Texas A&M University have developed the first molecular therapeutic for Angelman syndrome to advance into clinical development.

Development 98

Development Research Clinical Development 98

Drug Discovery Today

NOVEMBER 7, 2023

Cancer Research UK, and the KWF Dutch Cancer Society (KWF), two of the world’s largest charitable funders of cancer research, announce a new multi-project strategic partnership to advance promising therapeutic agents for cancer through early clinical development.

Clinical Development 49

Clinical Development Development Research Drugs 49

Pharmaceutical Technology

APRIL 17, 2024

Ftortiazinon is under clinical development by Gamaleya Federal Research Center of Epidemiology and Microbiology and currently in Phase II for Urinary Tract Infections.

Research 100

Research Clinical Development Development 100

Advarra

OCTOBER 4, 2023

When it comes to clinical development, precision, compliance, and quality assurance are paramount. For clinical development organizations, an effective CAPA serves as an essential compass, directing a path towards continuous improvement while maintaining steadfast regulatory compliance.

Compliance 52

Compliance Clinical Development Development Clinical Trials 52

Pharma Mirror

FEBRUARY 25, 2022

This joint service offering, DRIVE™-Biologics, will leverage Abzena’s strength in design and developability, and cell line development through to commercial manufacturing.

Clinical Development 130

Clinical Development Development Manufacturing Medicine 130

Pharmaceutical Technology

APRIL 3, 2023

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio.

Development 246

Development Drugs Clinical Development Licensing 246

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). Astellas and Sutro will expedite the development of iADCs for three different biological targets. It can potentially enhance the anti-cancer effect.

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Lab-specific industrial co-bots can carry out both complex and repetitive tasks such as liquid handling.

Development 311

Development Drugs Pharma Companies Life Science 311

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. Under the joint research project, a new research team will be set up at the BioMed X Institute in Heidelberg, Germany. The companies will select a varied group of skilled researchers for the project.

Development 246

Development Drugs In-Vivo Engineer 246

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 3, 2023

Researchers at the Indian Institute of Science (IISc) have found that picolinic acid, a natural compound produced by mammalian cells, can block several disease-causing viruses such as SARS-CoV-2 and influenza A viruses. The Institute is now looking for partners in pharma companies to pursue further clinical development of the findings.

Pharma Companies 160

Pharma Companies Research Clinical Development Development 160

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong.

Development 64

Development Research Drugs Antibody 64

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharmaceutical Technology

MAY 12, 2023

Angelini Pharma has entered an exclusive global development and commercialisation deal with JCR Pharmaceuticals to develop and commercialise new biologic therapies to treat epilepsy. The company will receive reimbursement of research expenses and an upfront payment, and will also be eligible for $505.5m

Development 130

Development Clinical Development Research 130

Worldwide Clinical Trials

DECEMBER 7, 2023

Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. What Differentiates Mid-Size CROs?

Clinical Development 333

Clinical Development Clinical Trials Clinical Trials Trials 333

Pharmaceutical Technology

JANUARY 4, 2024

TBO-309 is under clinical development by Heart Research Institute and currently in Phase II for Acute Ischemic Stroke.

Research 100

Research Clinical Development Development 100

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development 130

Development Drugs Licensing Licensing 130

Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. Astellas could pay Cullgen up to $85m upon using its license option regarding the deal.

Protein 130

Protein Development Licensing Licensing 130

Pharmaceutical Technology

MARCH 20, 2023

Predictive Oncology and Cancer Research Horizons, a part of Cancer Research UK (CRUK), has collaborated to drive cancer drug development using the former’s PEDAL platform. This helps in more informed drug-tumour type combinations selection for clinical development.

Research 130

Research Clinical Development Drugs Development 130

Pharmaceutical Technology

MARCH 30, 2023

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research and the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) have launched the Lupus Research Alliance (LRA) in a bid to advance research for the condition. Asian, Hispanic, and Native American women are also at higher risk.

Development 162

Development Drugs FDA Approval Clinical Development 162

Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicycle will receive an upfront payment of $45m and up to $1.7bn as potential development and commercially based milestone fees.

Development 162

Development Manufacturing Protein Clinical Development 162

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The post Ono Pharmaceutical enters research deal with Monash University appeared first on Pharmaceutical Technology.

Research 130

Research Antibody Sales Development 130

BioPharma Reporter

APRIL 8, 2024

In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.

Development 85

Development Drugs Research Clinical Development 85

Outsourcing Pharma

MARCH 24, 2022

The companyâs analysis of clinical research activity in the region shows the conflict will have long-lasting effects that reach beyond the countryâs borders.

Clinical Development 59

Clinical Development Development Clinical Research Research 59

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 16, 2024

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, has announced a strategic alliance to accelerate access to oncology clinical (..)

Clinical Trials 148

Clinical Trials Clinical Trials Trials Clinical Research 148

Drug Discovery World

MARCH 10, 2023

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. If successful in clinical trials the investigational candidates may have the potential to offer cancer patients access to new targeted treatment options.

Antibody 98

Antibody Research Clinical Trials Clinical Trials 98

pharmaphorum

MARCH 17, 2021

Hopes that the UK government would step in to support charity-funded medical research were dashed when the sector received no mention in the Budget despite campaigns to secure additional support. So, when research is at risk, what are the potential consequences for patient care, the wider research community, and UK plc in general?

Research 98

Research Development Life Science Clinical Development 98

Worldwide Clinical Trials

APRIL 15, 2024

As the clinical research landscape continually evolves, the choice of a Contract Research Organization (CRO) partner can significantly impact the success of drug development programs.

Clinical Trials 130

Clinical Trials Clinical Trials Clinical Development Clinical Research 130

Pharmaceutical Technology

AUGUST 4, 2022

Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. Roche and Poseida will also partner in a research programme for creating and developing next-generation features and enhancements for allogeneic CAR-T therapies.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Li, president, Merck Research Laboratories, until his retirement. Li, president, Merck Research Laboratories, until his retirement.

Clinical Development 52

Clinical Development Development Vaccination Vaccine 52

Pharmaceutical Technology

FEBRUARY 21, 2023

Japanese firm Teijin has announced its basic agreement on a capital and business alliance with Axcelead to establish a drug discovery research joint venture (JV) company. In addition to supporting drug discovery research, the new company will investigate and acquire candidate compounds for new drugs.

Research 130

Research Drugs Clinical Development Development 130

Drug Discovery World

JANUARY 3, 2023

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets. . The post Research partners hope to develop novel antibody-drug conjugates appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Development Research Drugs 52

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1.

Vaccination 130

Vaccination Vaccine Development Immune Response 130